Altered placental oxidative stress status in gestational diabetes mellitus

Placenta

Volumn 25, Issue 1, 2004, Pages 78-84

  Coughlan, M T ^a   Vervaart, P P ^b   Permezel, M ^a   Georgiou, H M ^a   Rice, G E ^a  

^a UNIVERSITY OF MELBOURNE   (Australia)

^b ROYAL CHILDREN'S HOSPITAL   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

8 ISOPROSTAGLANDIN F2 ALPHA; ANTIOXIDANT; BIOCHEMICAL MARKER; CARBONYL DERIVATIVE; COPPER ZINC SUPEROXIDE DISMUTASE; GLUCOSE; GLUTATHIONE PEROXIDASE; LACTATE DEHYDROGENASE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; EXPLANT; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; HUMAN TISSUE; HYPOTHESIS; NON INSULIN DEPENDENT DIABETES MELLITUS; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PLACENTA; PREGNANCY DIABETES MELLITUS; PRIORITY JOURNAL; PROSTAGLANDIN RELEASE; PROTEIN DETERMINATION;

EID: 0347765961     PISSN: 01434004     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0143-4004(03)00183-8     Document Type: Article

References (40)

1. Metzger BE, Coustan DR. Proceedings of the fourth international workshop-conference on gestational diabetes mellitus. Diabetes Care 1998;21(Suppl. 2):B1-167.
2. King H. Epidemiology of glucose intolerance and gestational diabetes in women of childbearing age. Diabetes Care 1998;21(Suppl. 2):B9-13.
3. Dornhorst A, Bailey PC, Anyaoku V, Elkeles RS, Johnston DG, Beard RW. Abnormalities of glucose tolerance following gestational diabetes. QJM 1990;284:1219-28.
4. Pendergrass M, Fazioni E, De Fronzo R. Non-insulin-dependent diabetes mellitus and gestational diabetes mellitus: same disease, another name? Diabetes Rev 1995;3:566-83.
5. Halliwell B. Antioxidants and human disease: A general introduction. Nutr Rev 1997;55:S44-52.
6. Baynes JW. Role of oxidative stress in development of complications in diabetes. Diabetes 1991;40:405-12.
7. West IC. Radicals and oxidative stress in diabetes. Diabet Med 2000; 17:171-80.
8. Coughlan MT, Oliva K, Georgiou HM, Permezel JHM, Rice GE. Glucose-induced release of TNF-α from human placental and adipose tissues in gestational diabetes mellitus. Diabet Med 2001;18:921-7.
9. Morrow JD. The isoprostanes: their quantification as an index of oxidant stress status in vivo. Drug Metab Rev 2000;32:377-85.
10. Leitch I, Osmond D, Falconer J, Clifton V, Walters W, Read M. Vasoactive effects of 8-epi-prostaglandin-F2alpha in the human placenta in vitro. J Soc Gynecol Investig 1999;6:195A.
11. Morrow JD, Minton TA, Roberts LJ. The F2-isoprostane, 8-epiprostaglandin F2 alpha, a potent agonist of the vascular thromboxane/ endoperoxide receptor, is a platelet thromboxane/endoperoxide receptor antagonist. Prostaglandins 1992;44:155-63.
12. Pratico D, Smyth EM, Violi F, FitzGerald GA. Local amplification of platelet function by 8-Epi prostaglandin F2alpha is not mediated by thromboxane receptor isoforms. J Biol Chem 1996;271:14916-24.
13. Wentzel P, Eriksson UJ. 8-Iso-PGF(2alpha) administration generates dysmorphogenesis and increased lipid peroxidation in rat embryos in vitro. Teratology 2002;66:164-8.
14. 2-like compounds are produced in vivo in humans by a non-cyclooxygenase, free radical catayzed mechanism. Proc Natl Acad Sci U S A 1990;87:9383-7.
15. 2α levels are elevated in individuals with non-insulin dependent diabetes mellitus. FEBS Lett 1995; 368:225-9.
16. Devaraj S, Hirany SV, Burk RF, Jialal I. Divergence between LDL oxidative susceptibility and urinary F-2-isoprostanes as measures of oxidative stress in Type 2 diabetes. Clin Chem 2001;47:1974-9.
17. Davi G, Ciabattoni G, Consoli A, Mezzetti A, Falco A, Santarone S et al. In vivo formation of 8-iso-prostaglandin F-2 alpha and platelet activation in diabetes mellitus. Circulation 1999;99:224-9.
18. Gerber RT, Holemans K, O'Brien-Coker I, Mallet AI, van Bree R, Van Asschem FA et al. Increase of the isoprostane 8-isoprostaglandin F-2alpha in maternal and fetal blood of rats with streptozotocin-induced diabetes: evidence of lipid peroxidation. Am J Obstet Gynecol 2000; 183:1035-40.
19. Grune T, Reinheckel T, Davies KJ. Degradation of oxidized proteins in mammalian cells. FASEB J 1997;11:526-34.
20. Stadtman ER, Berlett BS. Reactive oxygen-mediated protein oxidation in aging and disease. Drug Metab Rev 1998;30:225-43.
21. Dalle-Donne I, Giustarini D, Colombo R, Rossi R, Milzani A. Protein carbonylation in human diseases. Trends Mol Med 2003;9:169-76.
22. Konukoglu D, Kemerli GD, Sabuncu T, Hatemi HH. Protein carbonyl content in erythrocyte membranes in type 2 diabetic patients. Horm Metab Res 2002;34:367-70.
23. Cederberg J, Basu S, Eriksson UJ. Increased rate of lipid peroxidation and protein carbonylation in experimental diabetic pregnancy. Diabetologia 2001;44:766-74.
24. Walsh SW. Maternal-placental interactions of oxidative stress and anti-oxidants in preeclampsia. Seminars In Reproductive Endocrinology 1998; 16:93-104.
25. Myatt L, Eis AL, Brockman DE, Kossenjans W, Greer IA, Lyall F. Differential localization of superoxide dismutase isoforms in placental villous tissue of normotensive, pre-eclamptic, and intrauterine growth-restricted pregnancies. J Histochem Cytochem 1997;45:1433-8.
26. Takehara Y, Yoshioka T, Sasaki J. Changes in the levels of lipoperoxide and antioxidant factors in human placenta during gestation. Acta Med Okayama 1990;44:103-11.
27. Hoffman L, Nolan C, Wilson JD, Oats JJN, Simmons D. Gestational diabetes mellitus - management guidelines. The Australasian Diabetes in Pregnancy Society. MJA 1998;169:93-7.
28. 2 from human placenta. J Endocrinol 1999;160:291-6.
29. Farrugia W, Ho PW, Rice GE, Moseley JM, Permezel M, Wlodek ME. Parathyroid hormone-related protein(1-34) in gestational fluids and release from human gestational tissues. J Endocrinol 2000;165:657-62.
30. Natarajan R, Lanting L, Gonzales N, Nadler J. Formation of an F2-isoprostane in vascular smooth muscle cells by elevated glucose and growth factors. Am J Physiol 1996;271:H159-65.
31. Wentzel P, Welsh N, Eriksson UJ. Developmental damage, increased lipid peroxidation, diminished cyclooxygenase-2 gene expression, and lowered prostaglandin E2 levels in rat embryos exposed to a diabetic environment. Diabetes 1999;48:813-20.
32. Wang Y, Walsh SW. Increased superoxide generation is associated with decreased superoxide dismutase activity and mRNA expression in placental trophoblast cells in pre-eclampsia. Placenta 2001;22:206-12.
33. Awasthi YC, Dao DD. Glutathione-mediated detoxification mechanisms of human placenta. Placenta 1981;3:289-301.
34. Kinalski M, Sledziewski A, Telejko B, Kowalska I, Kretowski A, Zarzycki W et al. Lipid peroxidation, antioxidant defence and acid-base status in cord blood at birth: the influence of diabetes. Horm Metab Res 2001;33:227-31.
35. Pustovrh C, Jawerbaum A, Sinner D, Pesaresi M, Baier M, Micone P et al. Membrane-type matrix metalloproteinase-9 activity in placental tissue from patients with pre-existing and gestational diabetes mellitus. Reprod Fertil Dev 2000;12:269-75.
36. Kamath U, Rao G, Raghothama C, Rai L, Rao P. Erythrocyte indicators of oxidative stress in gestational diabetes. Acta Paediatr 1998;87:676-9.
37. Loven A, Romem Y, Pelly IZ, Holcberg G, Agam G. Copper metabolism - a factor in gestational diabetes? Clin Chim Acta 1992; 213:51-9.
38. Solomon CG, Willett WC, Carey VJ, Rich-Edwards J, Hunter DJ, Colditz GA et al. A prospective study of pregravid determinants of gestational diabetes mellitus. JAMA 1997;278:1078-83.
39. Davi G, Guagnano MT, Ciabattoni G, Basili S, Falco A, Marinopiccoli M et al. Platelet activation in obese women: role of inflammation and oxidant stress. JAMA 2002;288:2008-14.
40. Myatt L, Kossenjans W, Sahay R, Eis A, Brockman D. Oxidative stress causes vascular dysfunction in the placenta. J Matern Fetal Neonatal Med 2000;9:79-82.